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Chemotherapy-induced peripheral neurotoxicity (CIPN) is 
one of the major dose-limiting adverse events of widely used 
drugs in both the oncologic and hematologic setting (1). 
Among its cardinal symptoms, neuropathic pain is 
frequently present (2). In particular, the incidence of 
bortezomib-induced peripheral neurotoxicity (BIPN) 
and neuropathic pain ranges from 14–45% and 5–39%, 
respectively, in myeloma multiple patients. BIPN is more 
frequently developed in pretreated patients, compared to 
those being chemotherapy-naïve (3,4), and this difference 
mostly accounts for the wide variability in the observed 
incidence rates. Bortezomib is the first proteasome inhibitor 
introduced in clinical practice. The mechanisms underlying 
the pathogenesis of peripheral neurotoxicity in bortezomib-
treated patients are, yet, not fully elucidated (3,4). 
We read with great interest the recently published 
paper by Stockstill et al. (5), which sought to shed further 
light on the pathogenetic mechanisms of bortezomib-
associated neuropathic pain. The scientific background of 
the latter study was based on the increase of sphingolipid 
ceramide biosynthesis as pro-apoptotic signaling in cancer 
cells, together with the evidence that ceramide and other 
sphingolipid metabolites, specifically the sphingosine-1-
phosphate (S1P), are potent molecules with inflammatory 
and nociceptive actions. On that context, the authors 
demonstrated in preclinical in vivo models that bortezomib 
increased the S1P and ceramide levels, among others 
sphingolipid metabolism products, in dorsal horn spinal 
cord (DHSC) astrocytes. These astrocytes are activated 
by SP1 receptor 1 (SP1R), leading to neuroinflammation 
through the overexpression of proinflammatory cytokines 
and over-release of the neurotransmitter glutamate in 
DHSC neurons, as fundamental mechanisms to generate 
the bortezomib-induced neuropathic pain. After showing 
increased levels of the main sphingolipid products in DHSC 
astrocytes as reaction to bortezomib exposure, two different 
approaches were applied to demonstrate the involvement 
of sphingolipid dysregulation in pain and prevent this 
adverse event of bortezomib administration. First, at a 
pharmacological level, authors used the S1PR1 antagonists 
FTY720 (fingolimod) and NIBR14, which prevented 
the animals from developing mechanical allodynia and 
hyperalgesia. Second, from a loss-of-function perspective, 
they also used knockdown mutants of SPR1 expression in 
astrocyte [driven by glial fibrillary acidic protein (GFAP)] 
and siRNA for SPR1, and in line with the previous models, 
showed a delayed development of neuropathic pain 
compared with the control group. 
Moreover, researchers observed a parallel hyper-reactivity 
of DHSC astrocytes located in the lamina I and II and 
proinflammatory cytokines tumour necrosis factor (TNF) 
and interleukin-1β (IL-1β), whereas a decrease of anti-
inflammatory cytokines IL-1 and IL-4 levels was also 
noted. In addition, the increased labeling of GFAP and 
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high pro-inflammatory cytokine levels in the DHSC were 
reverted by the administration of the S1PR1 antagonist 
FTY720 (fingolimod). As result of this observation, the 
authors suggest a feed-forward loop between inflammatory 
cytokines and sphingolipid dysregulation on the basis of 
the ability of TNF and IL-1β to activate the major enzymes 
involved in the biosynthesis of ceramide and S1P pathways, 
according to previously published evidence from other 
groups (6). To fully explore the ability of SP1 in modulating 
the function of nervous system pain pathways, they also 
recorded the excitatory postsynaptic currents from neurons, 
which receive input from the primary afferents in the spinal 
outer lamina II. 
The analysis of the experimental results showed an increase 
in both the frequency and amplitude of postsynaptic 
currents, in bortezomib-treated group. Furthermore,  the 
samples from animals (rats) co-treated with the S1PR1 
antagonist demonstrated a decreased frequency of synaptic 
currents, while the inverse effect (increase) was noted with 
the administration of an S1PR1 agonist. The interpretation 
of these observations thoroughly supports the implication 
of bortezomib in the alterations of glutamatergic signaling 
in DHSC neurons, driven by the S1PR1 activation at the 
presynaptic level. 
Finally, the authors suggest that the relationship 
between the pro-inflammatory cytokine state and the 
sphingolipid dysregulation, together with the increase in 
the glutamatergic signaling may promote, reinforce and/or 
maintain the neuronal sensitization in the central nervous 
system (CNS). Moreover, they propose as potential useful 
treatment approach the use of S1PR1 antagonist drugs, 
which are already available in clinical practice to treat other 
CNS disorders.
Despite the interesting and relevant findings reported 
by Stockstill and collaborators (5), several points need 
clarification and contextualization. Generally, there is a 
debate and controversy among the researchers in the field 
regarding which are the appropriate animal models to 
use for testing CIPN. Some investigators use treatment 
schedules consisting of short course and low doses of drug 
administration. These models develop neuropathic pain 
features that are related with the cytostatic administration, 
as in the Stockstill et al. paper, and are used to explore 
the CIPN pathogenesis and new treatments strategies to 
alleviate the neuropathic component of pain. Noteworthy, 
neuropathological and/or nerve conduction impairments 
are required to establish the diagnosis of peripheral 
neuropathy. However, it is uncertain if these treatment 
schedules are capable to experimentally induce CIPN with 
features clinically resembling it in cancer patients. In fact, 
the single bortezomib doses used by the authors were low, 
even if chemotherapy was administrated during a more 
prolonged time, compared to the single dose used in other 
animal models in which impairments in behavioral and 
nerve conduction studies were evident, and also nerve and 
dorsal root ganglia histopathological abnormalities were 
reported (7,8). Taken into account that the cumulated dose 
is the main risk factor to develop CIPN in chemotherapy 
treated patients (1), it sounds rational that the models 
with more extended schedules and higher single dose 
drug administration, thus reaching total equivalent 
cumulated doses similar to the patients, are the most 
appropriate to characterize and investigate the pathogenesis 
of CIPN through evidence of neuropathological and 
neurophysiological abnormalities. In addition, another 
point in the experimental procedure that needs clarification 
is whether the researchers were blinded to treatments and 
randomization when conducting behavioral tests, as this 
in our view consist a crucial issue in any animal behavioral 
assessment. 
On the other hand, it is intriguing why the authors have 
not extended their research on sphingolipid dysregulation 
and on the effects of the SP1R blockade in Schwann and 
satellite cells, or even in dorsal root neurons, especially 
when it is well known that bortezomib is not able cross 
the blood brain barrier, and its main neurotoxic effects 
are in the peripheral nervous system, both in patients and 
animal models (3,4,6,7). Although bortezomib cannot 
penetrate into the CNS, the authors link the dysregulation 
on sphyngolipid metabolism of DHSC astrocytes with a 
peripheral increase in pro-inflammatory cytokines induced 
by the bortezomib exposure. In support of their assumption, 
it is previously demonstrated in an experimental model of 
chronic bortezomib exposure, a predominant increase in 
TNF and IL-6 expression on dorsal root ganglia neurons, 
mainly in the small size neurons, compared to spinal cord 
and peripheral nerve. Moreover, it was also evident that 
drugs blocking the TNF action, also partially prevent the 
neurotoxicity induced by bortezomib (9). 
It is well known that bortezomib-induced peripheral 
nerve damage can be characterized as a pure sensory 
neuronopathy (3,4,6,7). However, if the pro-inflammatory 
environment is responsible of the DHSC astrocytes 
changes, it still remains to be explained why these 
inflammatory cytokines have not evoked relevant changes 
in motor or sensory neurons, which are also exposed to 
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this inflammatory environment. Likewise, further research 
is warranted to elucidate why the enhanced release of 
glutamate from presynaptic vesicles by S1P; the second 
contributing factor to neuropathic pain genesis according 
to the authors’ results, have not produced collateral effects 
on motor neurons, especially over the small and vulnerable 
glutamate motor neurons (10). 
Another significant question that arises from the paper 
by Stockstill et al. (5) relates with the specificity of the 
sphingolipid dysregulation mechanism as a contributing 
factor for generating bortezomib-induced neuropathic 
pain. Interestingly, the same research group has previously 
involved the same dysregulated pathway in the pathogenesis 
of paclitaxel-induced neuropathic pain (11). To clarify this 
point, it is advisable to further test the effect of carfilzomib 
over the DHSC astrocyte sphingolipid metabolism wields, 
as this drug is a second-generation proteasome inhibitor 
without exerting relevant neurotoxic adverse events (12).
The last but not least questionable point upon the 
Stockstill et al. (5) publication concerns the assumed 
recommendation to treat patients with FTY720 (fingolimod) 
which is already available in clinical practice, to treat CNS 
disorders, such as multiple sclerosis. Patients with multiple 
myeloma or other hematologic malignancies are at high risk 
to be immunocompromised. Therefore, a drug impairing 
the ability of cytotoxic CD8 T cells to destroy their target 
cells, thus further compromising the immunity (13), may 
not be the best approach for alleviating the neuropathic pain 
component in these patients. 
Nevertheless, in our opinion the study by Stockstill 
et al. (5) is of significance, because it is presenting for the 
first-time experimental results to support the significance 
of sphingolipid dysregulation in the pathogenesis of 
bortezomib-induced neuropathic pain, thus potentially 
shedding further light in the pathogenetic mechanism of 
BIPN as a whole. Thus far, the main mechanisms involved 
in the BIPN are related with the cytoskeletal alterations 
caused by an increased microtubule stabilization due to 
α-tubulin polymerization, mitochondrial dysfunction, 
dysregulation of neurotrophins, and neuroinflammation 
processes mediated by neuronal expression of IL-6 and 
tumor necrosis factor (3,4). The role of sphingolipid 
dysregulation can indeed play a potential role in the 
painful phenotype of BIPN, as Stockstill and collaborators 
have demonstrated. However, to reinforce this potential 
involvement, similar results have to be replicated in 
appropriate chronic BIPN models, and the assessment 
should ideally have to be extended to the peripheral nervous 
cellular compartment (Schwann and satellite cells, and 
sensory dorsal root ganglia neurons).
Finally, it is clinically important to take into account 
several particular points to contextualize the BIPN research. 
CIPN in bortezomib-treated patients possess distinctive 
and intriguing characteristics compared with other forms 
of CIPN. First, this adverse effect might not be a class 
effect, as second-generation proteasome inhibitors, such 
as carfilzomib, are less neurotoxic than bortezomib (14), 
while being equally or more effective in treating multiple 
myeloma. Second, improvements in symptoms severity 
and a relatively quick resolution of BIPN occur after 
chemotherapy cessation in most patients and animal 
models with bortezomib-related CIPN. This reversibility 
of symptoms soon after chemotherapy discontinuation is 
contrary with the persistence of symptoms and notably 
slow neurological recovery that is observed in patients 
with CIPN related to other neurotoxic drugs, particularly 
platinums and taxanes (1). Last, the BIPN is more frequent 
in patients with multiple myeloma than in those with other 
cancers. This observation supports the possibility that 
multiple myeloma itself plays a part in the development 
of BIPN (15,16). As such, it should be emphasized that 
only fully considering the clinical phenotype of this toxic 
neuropathy, and accordingly, with the adequate adjust of the 
preclinical research settings, we would allow to shed further 
light on the pathogenesis of bortezomib-induced peripheral 
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